Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04493619
Recruitment Status : Recruiting
First Posted : July 30, 2020
Last Update Posted : October 30, 2020
Sponsor:
Information provided by (Responsible Party):
Plexxikon

Brief Summary:
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

Condition or disease Intervention/treatment Phase
Gynecologic Neoplasms Epithelial Ovarian Cancer Drug: PLX2853 Drug: Carboplatin Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 67 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Actual Study Start Date : August 11, 2020
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer
Drug Information available for: Carboplatin

Arm Intervention/treatment
Experimental: PLX2853 Phase 2a Monotherapy
Up to 26 evaluable subjects with ARID1A mutation-positive advanced gynecological malignancies will be enrolled.
Drug: PLX2853
PLX2853 tablets

Experimental: PLX2853 + Carboplatin Phase 1b/2a Combination Therapy

Phase 1b (PLX2853 + carboplatin combination): Up to 15 evaluable subjects with platinum-resistant EOC will be enrolled.

Phase 2a (PLX2853 + carboplatin combination): Up to 26 evaluable subjects with platinum-resistant EOC will be enrolled.

Drug: PLX2853
PLX2853 tablets

Drug: Carboplatin
Carboplatin IV injection, 5 mg•min/mL




Primary Outcome Measures :
  1. Phase 2a (PLX2853 monotherapy): overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [ Time Frame: From 8 weeks of treatment for only PLX2853 (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months. ]
  2. Phase 1b (PLX2853 + carboplatin combination): establish the MTD/RP2D for the combination of PLX2853 and carboplatin [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
  3. Phase 2a (PLX2853 + carboplatin combination): ORR as measured by RECIST v1.1 [ Time Frame: From 8 weeks of treatment with PLX2853 and Carboplatin (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months. ]

Secondary Outcome Measures :
  1. Incidence of TEAEs that are related to treatment (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
  2. Incidence of TEAEs that result in dose interruption, reduction or discontinuation (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
  3. Incidence of treatment-emergent ECG abnormalities (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
  4. Incidence of treatment-emergent laboratory abnormalities (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
  5. Duration Of Response (DOR) (both arms) [ Time Frame: From 8 weeks of treatment (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months. ]
    DOR will be calculated for each subject with a response as the number of days from the date of first response (PR or CR confirmed at least 28 days later) to the date of the first documented disease progression or date of death from any cause, whichever occurs first.

  6. Disease control rate (DCR) (both arms) [ Time Frame: From time of first dose until end of treatment, an average of 6 months. ]
    DCR will be calculated as the percentage of subjects with confirmed complete response (CR), Partial Response (PR), or Stable Disease (SD).

  7. Progression-free survival (PFS) (both arms) [ Time Frame: From time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 24 months. ]
    Progression-free survival (PFS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment (Cycle 1 Day 1) to the date of the first documented disease progression or date of death from any cause, whichever occurs first.

  8. Overall survival (OS) (both arms) [ Time Frame: From time of first dose until completion of long term follow-up, approximately 24 months. ]
    Overall survival (OS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment (Cycle 1 Day 1) to the date of death from any cause.

  9. PLX2853 PK parameter AUC0-last (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    AUC from time zero to time of last observed concentration hours postdose (AUC0-last).

  10. PLX2853 PK parameter AUC0-24 (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    AUC from time zero extrapolated to 24 hours (AUC0-24)

  11. PLX2853 PK parameter AUC0-∞ (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    AUC from time zero extrapolated to infinite time (AUC0-∞)

  12. PLX2853 PK parameter Cmax (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    Maximum observed concentration

  13. PLX2853 PK parameter Tmax (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    Time to maximum observed concentration

  14. PLX2853 PK parameter T1/2 (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    terminal elimination half-life (T1/2)

  15. PLX2853 PK parameter accumulation ratio at steady state (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    accumulation ratio at steady state



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years at the time of signing informed consent
  2. Histologically or cytologically confirmed diagnosis of 1 of the following, and must have measurable disease per RECIST v1.1:

    • Phase 2a (PLX2853 monotherapy): Any advanced gynecological malignancy (cervical, vaginal, vulvar, uterine, ovarian, fallopian tube, or primary peritoneal) with a known ARID1A mutation, that is intolerant to or refractory to all standard therapy known to confer clinical benefit.
    • Phase 1b and Phase 2a (PLX2853 + carboplatin combination):

    Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer).

  3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1
  4. Adequate organ function as demonstrated by laboratory values.
  5. Women of child bearing potential (defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal) must have a negative serum pregnancy test within 7 days prior to taking the first dose of study drug and, if sexually active, must agree to use a highly effective method of contraception (a contraception method with a failure rate <1% per year) and 1 additional barrier method from the time of the negative pregnancy test to 90 days after the last dose of study drug. Women of non-child bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
  6. Except as specified above for organ function, all drug-related toxicity from previous cancer therapy must be resolved (to Grade ≤1 or baseline per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [NCI CTCAE v5.0]) prior to study treatment administration (Grade 2: alopecia, hot flashes, decreased libido, or neuropathy is allowed).
  7. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements

Exclusion Criteria:

  1. Prior exposure to a bromodomain inhibitor
  2. Ongoing systemic infection requiring treatment with antibiotic, antiviral, or antifungal treatment
  3. Autoimmune hemolytic anemia or autoimmune thrombocytopenia
  4. Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
  5. Red blood cell or platelet transfusion within 14 days of Screening blood draw
  6. Known or suspected allergy to the investigational agent or any agent given in association with this study
  7. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 μg (NIH-ODS 2020).
  8. Use of strong inhibitors and inducers of CYP3A4 and 2C8
  9. Clinically significant cardiac disease
  10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption
  11. Non-healing wound, ulcer, or bone fracture
  12. Infection with HIV-1 or HIV-2. Exception: subjects with well-controlled HIV (e.g., CD4 >350/mm3 and undetectable viral load) are eligible.
  13. Current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid).
  14. Active known second malignancy with the exception of any of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    • Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years
    • Any other cancer from which the subject has been disease-free for ≥3 years
  15. Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1
  16. Hospitalization for subacute bowel obstruction within 28 days prior to Cycle 1 Day 1
  17. Receipt of anti-cancer therapy prior to Cycle 1 Day 1:

    • Chemotherapy, radiation therapy, or small molecule anti-cancer therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1
    • Immune therapy or other biologic therapy (e.g., monoclonal antibodies, antibody-drug conjugates) for the treatment of cancer within 21 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1 Subjects can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 28 days prior to treatment with study drug.
  18. Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed).
  19. Subjects who are pregnant or breast-feeding
  20. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol or would interfere with the study endpoints or the subject's ability to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04493619


Contacts
Layout table for location contacts
Contact: Kerry Inokuchi 1-510-647-4148 Kinokuchi@plexxikon.com

Locations
Layout table for location information
United States, Illinois
The University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 05841
Contact: Hatti Koning    773-834-5722    hkoning@medicine.bsd.uchicago.edu   
United States, Massachusetts
Massachusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Oladapo Yeku, MD, PhD    617-643-9354    oyeku@mgh.harvard.edu   
Contact: Kellie Redmond    617-643-0361    kredmond2@partners.org   
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
United States, Oklahoma
University of Oklahoma - Stephenson Cancer Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact    405-271-8001    PhaseI-Referrals@ouhsc.edu   
United States, Tennessee
Tennessee Oncology / Sarah Cannon Recruiting
Nashville, Tennessee, United States, 37203
Contact: AskSARAH https://sarahcannon.com/asksarah/    844-482-4812      
United States, Virginia
University of Virginia Health Systems Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Anne Gabel       AM7BD@hscmail.mcc.virginia.edu   
Virginia Cancer Specialists, PC Recruiting
Fairfax, Virginia, United States, 22031
Contact: Alexander Spira, MD       Alexander.Spira@usoncology.com   
United States, Washington
University of Washington / Seattle Cancer Care Alliance Recruiting
Seattle, Washington, United States, 98109
Contact: Elizabeth Swisher    206-543-3669    swishere@uw.edu   
Contact: Greg Wallace       gugynresearch@seattlecca.org   
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada
Contact: Amit Oza    (416) 946-2818    Amit.Oza@uhn.ca   
Sponsors and Collaborators
Plexxikon
Layout table for additonal information
Responsible Party: Plexxikon
ClinicalTrials.gov Identifier: NCT04493619    
Other Study ID Numbers: PLX124-03
First Posted: July 30, 2020    Key Record Dates
Last Update Posted: October 30, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Plexxikon:
PLX2853
Ovarian Cancer
ARID1A
Gynecological Malignancies
Carboplatin
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Genital Neoplasms, Female
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carboplatin
Antineoplastic Agents